eXoZymes Q2 Earnings Call Highlights

eXoZymes reported its process is now roughly 10 times more productive than during its March pilot, which produced more than 500 grams at 99.6% purity. The company expects to select a manufacturing partner by the end of Q3, identify a launch partner late in Q4, and target a product launch in the first half of 2027.

The company is developing cannabinoid analogs with federal grant support and evaluating five undisclosed molecules for nutraceutical, cosmetic and pharmaceutical applications. It plans to develop selected assets further before partnering, aiming to reduce risk and retain more value.

eXoZymes ended Q2 with $5.65 million in cash after raising $5.86 million in net proceeds through June financing transactions. The pre-revenue company reported a $2.88 million quarterly net loss and said its cash should fund operations and key initiatives into the end of 2026.

e XoZymes NASDAQ: EXOZ outlined progress toward commercializing its NCT program, including a reported tenfold increase in process productivity versus its March pilot campaign, while management said it expects to select a manufacturing partner by the end of the third quarter and identify a market launch partner toward the end of the fourth quarter. The company, which remains pre-revenue, said its targeted timeline is to launch an NCT product in the first half of 2027.

Executives also discussed government-supported research programs, an internal pipeline of potential future products and the company’s second-quarter financial position following June financing transactions.

eXoZymes’ initial pilot-scale NCT campaign, conducted with Cayman Chemical, scaled the process from one liter to 100 liters. Cayman independently operated the process based on the company’s technology-transfer package, producing more than 500 grams of NCT at 99.6% purity and converting 99% of feedstock into product, according to Korman.

Since that March pilot run, eXoZymes has focused on improving productivity. Korman said the company now obtains approximately 67% more NCT per liter of reaction volume, while the reaction is completed about five times faster. Combining those gains with other process improvements, the company said its process is now roughly 10 times more productive than it was during the pilot campaign.

“The pilot campaign in March demonstrated the process could work,” Korman said. “This productivity work here is what we believe makes it economically attractive.” He added that the company has shifted the process to commercially relevant unit operations rather than development-lab procedures.

The company cautioned that the timing and outcome of any technology transfer remain subject to factors described in its SEC filings.

Chief Commercial Officer Damien Perriman said partner selection is being evaluated on more than equipment and costs, emphasizing communication, collaboration and problem-solving capabilities during technology transfer. eXoZymes is also qualifying backup manufacturing options to support supply continuity as NCT demand grows.

The company said it has verified multiple suppliers for key production inputs and is pursuing an asset-light production model using external manufacturing partners rather than building its own facilities.

Perriman said regulatory activities, including GRAS preparation and supporting human studies, are part of the commercialization foundation. Management expects a commercial and marketing partner to provide branding, channel development, commercialization expertis...